Keytruda adds to chemo's effect in hard-to-treat lung cancer
US pharma giant Merck & Co (NYSE: MRK) has announced the first-time presentation of results from a post-hoc analysis of patients with liver or brain metastases from the Phase III KEYNOTE-189 trial.
A post-hoc analysis from KEYNOTE-189, which evaluated Keytruda in combination with pemetrexed (Alimta) and cisplatin or carboplatin in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) regardless of PD-L1 tumor expression and with no EGFR or ALK genomic tumor aberrations, was featured in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia.
The findings showed Keytruda in combination with chemotherapy reduced the risk of death by 38% in patients with liver metastases and by 59% in those with brain metastases compared to chemotherapy alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze